Azitra Expands ATR-04 Trial Eligibility to Patients With KRAS and MEK Inhibitor Rashes
The Phase 1/2 trial will include patients with rashes caused by KRAS and MEK inhibitors, in addition to those with EGFR-related rashes.
Related stories
APR Co. Q3 Operating Profit Rises 69% to 160.6 Billion Won
APR Co. reported Q3 operating profit of 160.6 billion won, up 69% from a year earlier.
M impact | EQUITY | Oct 30, 2026, 01:10 AM UTC
South Korea’s KOSPI Drops More Than 4%; Sell-Sidecar Triggered
M impact | EQUITY | Oct 30, 2026, 01:09 AM UTC
Way 2 VAT Reports Q3 FY26 Revenue of A$1.90 Million
M impact | EQUITY | Oct 30, 2026, 01:09 AM UTC
Vale Reports Third-Quarter Profit of $1.255 Billion, Down From $2.685 Billion
Vale reported third-quarter earnings of $1.255 billion, or $0.29 per share, compared with $2.685 billion, or $0.63 per share, a year earlier. Revenue rose 1.7%.
M impact | EQUITY | Oct 30, 2026, 01:08 AM UTC
Monsanto gana por unanimidad primer juicio por glifosato
El fallo del Supremo de EE. UU. precedió la victoria unánime de Monsanto en el juicio, según el titular.
M impact | EQUITY | Oct 30, 2026, 01:08 AM UTC
Bayer’s Monsanto Wins Missouri Glyphosate Case Unanimously
M impact | EQUITY | Oct 30, 2026, 01:08 AM UTC